Tue, June 16, 2026 at 6:04 AM UTC
FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little/File Photo
BEIJING, June 16 (Reuters) – Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill “very soon,” CEO Mike Doustdar said Tuesday, in a move to catch up with rival Eli Lilly in the world’s second-largest pharmaceutical market.
(Reporting by Andrew Silver; Editing by Christopher Cushing)